The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
E Parasido, GS Avetian, A Naeem… - Molecular Cancer …, 2019 - europepmc.org
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells
E Parasido, GS Avetian… - Molecular …, 2019 - mdanderson.elsevierpure.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells
E Parasido, GS Avetian, A Naeem, G Graham… - Molecular Cancer …, 2019 - osti.gov
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells
E Parasido, GS Avetian, A Naeem… - Molecular cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells
E Parasido, GS Avetian, A Naeem… - Molecular Cancer …, 2019 - ohsu.elsevierpure.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.
E Parasido, GS Avetian, A Naeem… - Molecular cancer …, 2019 - escholarship.org
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells
E Parasido, GS Avetian, A Naeem… - Molecular Cancer …, 2019 - pure.johnshopkins.edu
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
[HTML][HTML] The sustained induction of c-Myc drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells.
E Parasido, G Avetian, A Naeem… - Molecular cancer …, 2019 - ncbi.nlm.nih.gov
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
The sustained induction of c-MYC drives nab-paclitaxel resistance in primary pancreatic ductal carcinoma cells
E Parasido, GS Avetian, A Naeem… - Molecular Cancer …, 2019 - ohsu.pure.elsevier.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease with limited and,
very often, ineffective medical and surgical therapeutic options. The treatment of patients …
very often, ineffective medical and surgical therapeutic options. The treatment of patients …